Insider Selling: Corcept Therapeutics Incorporated (CORT) Insider Sells 8,000 Shares of Stock

Corcept Therapeutics Incorporated (NASDAQ:CORT) insider Robert S. Fishman sold 8,000 shares of the stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $16.60, for a total transaction of $132,800.00. Following the transaction, the insider now directly owns 8,000 shares of the company’s stock, valued at approximately $132,800. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Shares of Corcept Therapeutics Incorporated (NASDAQ CORT) traded down $0.50 on Friday, hitting $14.59. 3,660,000 shares of the stock were exchanged, compared to its average volume of 2,410,000. Corcept Therapeutics Incorporated has a fifty-two week low of $7.86 and a fifty-two week high of $25.96. The firm has a market cap of $1,670.00, a price-to-earnings ratio of 50.31 and a beta of 1.68.

A number of equities analysts recently weighed in on CORT shares. Piper Jaffray Companies set a $30.00 price objective on shares of Corcept Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, October 31st. BidaskClub cut shares of Corcept Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Wednesday. Stifel Nicolaus decreased their price target on shares of Corcept Therapeutics from $25.00 to $20.00 and set a “buy” rating for the company in a research report on Monday. Finally, Zacks Investment Research cut shares of Corcept Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, January 3rd. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Corcept Therapeutics has a consensus rating of “Buy” and an average price target of $21.00.

A number of large investors have recently made changes to their positions in the stock. Suntrust Banks Inc. raised its stake in Corcept Therapeutics by 4.0% during the 2nd quarter. Suntrust Banks Inc. now owns 12,308 shares of the biotechnology company’s stock worth $145,000 after acquiring an additional 471 shares in the last quarter. TIAA CREF Investment Management LLC increased its stake in Corcept Therapeutics by 0.7% in the second quarter. TIAA CREF Investment Management LLC now owns 347,171 shares of the biotechnology company’s stock valued at $4,097,000 after purchasing an additional 2,360 shares during the period. Strs Ohio increased its stake in Corcept Therapeutics by 4.1% in the fourth quarter. Strs Ohio now owns 60,800 shares of the biotechnology company’s stock valued at $1,098,000 after purchasing an additional 2,400 shares during the period. PNC Financial Services Group Inc. increased its stake in Corcept Therapeutics by 52.6% in the second quarter. PNC Financial Services Group Inc. now owns 9,837 shares of the biotechnology company’s stock valued at $116,000 after purchasing an additional 3,390 shares during the period. Finally, Swiss National Bank increased its stake in Corcept Therapeutics by 3.2% in the fourth quarter. Swiss National Bank now owns 143,200 shares of the biotechnology company’s stock valued at $2,586,000 after purchasing an additional 4,500 shares during the period. Hedge funds and other institutional investors own 65.31% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright and trademark laws. The original version of this report can be viewed at https://www.americanbankingnews.com/2018/02/09/insider-selling-corcept-therapeutics-incorporated-cort-insider-sells-8000-shares-of-stock.html.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor (GR).

Insider Buying and Selling by Quarter for Corcept Therapeutics (NASDAQ:CORT)

Receive News & Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply